“Ozempic” filled many headlines in 2023, as the GLP-1 drug has proven effective and popular when it comes to weight loss – despite its original mandate being focused on diabetes.
But how many Canadian employers offer such drugs as part of employee benefits?
Sixty-six per cent provide coverage for GLP-1 drugs for diabetes only, while 17 per cent provide coverage for both diabetes and weight loss, according to a recent survey from the International Foundation of Employee Benefit Plans.
